ArticlebioRxiv : the preprint server for biology2025
A revised model of nuclear actin import: Importin 9 competes with cofilin, profilin, and RanGTP for actin binding.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
5 authors.
Funding
Abstract
While predominantly studied in cytoplasmic contexts, actin plays critical roles in the nucleus, regulating chromatin accessibility and remodeling, transcription, and DNA damage repair. Cell-based studies have contributed to a widely accepted model in which the import factor Importin 9 (IPO9) acts in concert with the actin filament-severing protein cofilin to transport actin into the nucleus. The classical nuclear localization signal on cofilin is thought to anchor IPO9 to cofilin-bound actin monomers, driving the formation of an import-competent tripartite actin•cofilin•IPO9 complex. In striking contradiction to this established model of actin import, we demonstrate that IPO9 directly binds to monomeric actin with mid-nanomolar affinity and, rather than promoting IPO9•actin complex formation, cofilin competitively inhibits binding of IPO9 to actin. We further report competitive binding for monomeric actin between IPO9 and the canonical actin monomer-sequestering protein, profilin. As cofilin and profilin are both capable of binding actin monomers at the barbed face, our results are consistent with a model in which IPO9 binds an overlapping portion of this interface. In further support, we demonstrate that IPO9 modestly occludes the barbed face of actin monomers, decreasing the rate of filament formation, and exhibits minimal filamentous actin binding. Finally, we identify unexpected affinity between the nuclear import release factor RanGTP and monomeric actin; however, a tripartite IPO9•actin•RanGTP complex does not form. The competitive interactions observed between IPO9 and cytoplasmic actin-binding proteins suggest dynamically coupled equilibria mediate the nuclear transport of actin monomers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.